It is likely that FDA approval will come first for the use of anti-CD5 and anti-CD7 CAR T cell therapies for T cell leukemias and lymphomas; however, this could help pave the way for its future use in treating patients with severe T cell-mediated autoimmune diseases. This evidence concerns the gene CD7 and autoimmune disease.